Isotechnika Inc. completes critical study

26-Nov-2007

Isotechnika Inc. announced the results from the rat carcinogenicity study for its lead immunosuppressive drug, ISA247. ISA247 did not exhibit any carcinogenicity up to the highest doses tested in male and female rats over a two year period.

Carcinogenicity studies are required by the United States Food and Drug Administration (FDA) and other Regulatory Authorities and are a critical part of the package submitted for marketing approval. Carcinogenicity studies are performed by administering a range of doses of a drug, including a dose considerably higher than the anticipated clinical dose for a period of two years. This timeframe is equivalent to administering the drug over a lifetime in humans.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance